Yuflyma (adalimumab-aaty) vs Idacio (adalimumab-aacf)
Yuflyma (adalimumab-aaty) vs Idacio (adalimumab-aacf)
Yuflyma (adalimumab-aaty) and Idacio (adalimumab-aacf) are both biosimilar medicines to the reference biologic Humira (adalimumab), indicated for the treatment of various inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. The main differences between the two may lie in their formulation, inactive ingredients, or the delivery device used for administration, which can affect individual tolerance or preference. When deciding between Yuflyma and Idacio, it is important for patients to consult with their healthcare provider to consider factors such as individual response, potential side effects, cost, insurance coverage, and ease of use based on the available devices.
Difference between Yuflyma and Idacio
| Metric | Yuflyma (adalimumab-aaty) | Idacio (adalimumab-aacf) |
|---|---|---|
| Generic name | Adalimumab-aaty | Adalimumab-aacf |
| Indications | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis |
| Mechanism of action | Tumor necrosis factor (TNF) blocker | Tumor necrosis factor (TNF) blocker |
| Brand names | Yuflyma | Idacio |
| Administrative route | Subcutaneous injection | Subcutaneous injection |
| Side effects | Infections, injection site reactions, headache, rash | Infections, injection site reactions, headache, rash |
| Contraindications | Severe infections, hypersensitivity to active substance or excipients | Severe infections, hypersensitivity to active substance or excipients |
| Drug class | Monoclonal antibody | Monoclonal antibody |
| Manufacturer | Celltrion Healthcare Co., Ltd. | Fresenius Kabi Deutschland GmbH |
Efficacy
Introduction to Yuflyma (adalimumab-aaty)
Yuflyma (adalimumab-aaty) is a biosimilar to the reference medicine Humira (adalimumab) and has been approved for the treatment of several inflammatory conditions, including rheumatoid arthritis (RA). Rheumatoid arthritis is a chronic autoimmune disease characterized by inflammation of the joints, which can lead to joint damage and disability. Yuflyma works by targeting and inhibiting tumor necrosis factor (TNF), a substance in the body that contributes to inflammation in RA.
Efficacy of Yuflyma in Rheumatoid Arthritis
The efficacy of Yuflyma in the treatment of rheumatoid arthritis has been demonstrated in clinical trials where it was compared with the reference product, Humira. In these trials, Yuflyma showed equivalent efficacy in reducing the signs and symptoms of RA, achieving similar rates of disease control and improvement in physical function. Patients treated with Yuflyma experienced significant relief from joint pain and swelling, which are hallmark symptoms of RA.
Introduction to Idacio (adalimumab-aacf)
Idacio (adalimumab-aacf) is another biosimilar to Humira and is indicated for the same conditions as Yuflyma, including rheumatoid arthritis. Like Yuflyma, Idacio is designed to target TNF, thereby reducing the inflammatory response that leads to the symptoms and progression of RA. The development of biosimilars like Idacio provides more treatment options for patients with RA and can contribute to the overall management of the disease.
Efficacy of Idacio in Rheumatoid Arthritis
Idacio's efficacy in treating rheumatoid arthritis has been confirmed through rigorous clinical trials. These studies have shown that Idacio is highly similar to Humira in terms of safety, purity, and potency. Patients receiving Idacio have reported improvements in joint pain, swelling, and other symptoms associated with RA. The ability of Idacio to slow down the progression of joint damage and improve the quality of life for individuals with RA has been substantiated by clinical evidence.
Regulatory Agency Approvals
Yuflyma
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Idacio
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Yuflyma or Idacio today
If Yuflyma or Idacio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us